Observed Signal · Nov 10, 2026 · Funding · Source: techcrunch · Impact: 3/5 · Sentiment: Positive
Proximal Ventures Raises $27.5M for AI Drug Development Fund
Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.
This fundraise signals continued investor interest in AI applications for drug development, a niche but growing area within the broader AI and health tech ecosystems, potentially impacting marketing strategies for pharma services.
Track Kleiner Perkins Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Proximal Ventures raised $27.5 million for its debut venture fund.
- The fund targets pre-seed and seed-stage startups applying AI to drug development.
- Seven startups have been backed, including ChronicleBio.
- Investors include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments.
- Individual investors include Dimension Capital co-founders Nan Li and Zavain Dar.
Connected Companies & Entities
“Kleiner Perkins is a backer of Proximal Ventures.”
“Roche acquired Flatiron Health for $1.9 billion.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Reach Capital closes $265M Fund V for AI startups
Reach Capital, a San Francisco venture firm focused on education and impact, closed a $265 million Fund V to back AI founders building applications across learning, health, and work. The fund — raised in under six months — plans to invest $1 million to $10 million per company, targeting roughly 50 companies across pre-seed to Series A over the next three years. Limited partners named include Capricorn Investment Group, the Los Angeles Fire and Police Pensions, the LEGO Foundation, and College Board. Reach’s prior funds include a $215M Fund IV (2023) and a $165M Fund III (2021).
Orakl Oncology Raises €30M for AI Cancer Drug Prediction
Orakl Oncology, a French TechBio company, announced a €30 million ($34 million) Series A round co-led by Norrsken VC and Singular, with participation from InfraVia Capital Partners, Serena, Patient Autonome Fund managed by Bpifrance, Teampact Ventures, Plug and Play, and existing investors Verve Ventures VC, Speedinvest, and HCVC. The company uses AI and patient-derived tumor organoids to build 'virtual cancer patients' that predict drug performance in clinical trials, aiming to reduce the high failure rate in Phase 2 oncology trials. Orakl claims 90% accuracy in predicting clinical outcomes. The funding will expand its platform across more cancer types and geographies. Total funding now stands at €45 million.
Receive all future signals for Kleiner Perkins & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.